Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
GlobalData on MSN13d
Amgen’s Imdylltra wins conditional MHRA licence for lung cancer
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients
Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited ...
Reuters1mon
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit
Dec 18 - Amgen's (AMGN.O), opens new tab leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding ...